A SWOT Analysis Of AstraZeneca Plc And GlaxoSmithKline plc

What are the key factors affecting the investment proposition at pharmaceutical giants GlaxoSmithKline plc (LON:GSK) and AstraZeneca plc (LON:AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline

With a market capitalisation of £80bn, GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) is the sixth largest company in the FTSE 100.

Strengths
GlaxoSmithKline operates in a highly regulated market. Many of its top products are protected by patents that prevent competition moving in and stealing sales. This gives the company an enormous stream of high-margin cashflows.

Weaknesses
Despite everything that GlaxoSmithKline has going for it, only modest earnings per share growth of 7.7% is forecast from the business in 2014. The current 2014 P/E of 13.3 could begin to look over-generous if growth expectations decline.

Opportunities
As economic growth in emerging markets lifts millions into the middle class, a whole new market opens up for GlaxoSmithKline. If Glaxo can get back on track in China, the company could have another decade of earnings growth ahead of it.

Threats
Back in July of this year, Glaxo shocked the markets when it admitted that some of its staff may have bribed Chinese doctors. Last month, Glaxo reported that the disruption to its business in China led to a 61% sales decline in the world’s most populated country.

AstraZeneca

AstraZeneca (LSE: AZN)(NYSE: AZN.US) is smaller than Glaxo, with a market capitalisation of ‘just’ £41bn.

Strengths
Like any successful pharmaceutical, the business underlying AstraZeneca is high margin with a high level of repeat purchase. One of the biggest attractions of the shares is the current large dividend yield, which is forecast to come in at 5.3% for this year.

Weaknesses
Market fears over AstraZeneca’s so-called ‘patent cliff’ have held back the shares in recent years. If AstraZeneca does not bring more patented drugs into its portfolio, earnings could decline fast.

Opportunities
AstraZeneca is aware of the risk to earnings and has been busy making acquisitions. The recent purchase of Pearl Therapeutics brings a portfolio of respiratory drugs into the AstraZeneca stable. Shareholders will hope that the company can continue to identify suitable bolt-ons and use its financial firepower to get the company growing again.

Threats
The biggest risk to the shares is that the company’s current strategy fails to deliver growth. This would see the shares re-rated significantly. Though not expensive today, it is not difficult to imagine a scenario where AstraZeneca shares end up 30% lower.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> David does not own shares in any of the companies mentioned. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

Should I buy these UK shares for my portfolio?

This Fool has been searching for ways to capitalise on the commodity moves via UK shares. Here’s what he’s watching.

Read more »

Illustration of flames over a black background
Investing Articles

Just released: April’s higher-risk, high-reward stock recommendation [PREMIUM PICKS]

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

£9,000 in savings? Here’s a FTSE 100 stock I’d buy to target a £30,652 annual second income!

Our writer highlights one top FTSE 100 share that he thinks could help create a portfolio large enough for a…

Read more »

Light bulb with growing tree.
Investing Articles

62% down! Is the Ceres Power share price now a green energy bargain?

Annual results from the green energy firm showed a company on the cusp of doubling sales. So why has the…

Read more »

Investing Articles

3 mid-cap UK defence shares to consider buying in 2024

Defence budgets are soaring as global conflicts increase the threat landscape, so I'm examining the value proposition of three defence-related…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Hargreaves Lansdown investors have been buying dividend stocks BP and Shell. Should I?

Cherished dividend stocks BP and Shell have outperformed the FTSE 100 index so far in 2024. Paul Summers takes a…

Read more »

Young Asian man shopping in a supermarket
Dividend Shares

A 5% yield? Here’s the 3-year dividend forecast for Tesco shares

Jon Smith flags up the positive momentum for Tesco shares following the release of the full-year results and looks at…

Read more »

Investing Articles

Yields up to 12.3% 3 top shares investors should consider for a second income

Searching for ways to make a market-beating second income? These popular dividend stocks are worth serious consideration, says Royston Wild.

Read more »